An inflammatory myofibroblastic tumor (IMT) is a rare disease entity reported to arise in various organs. It is thought to be a neoplastic or reactive inflammatory condition,controversially. The treatment of choice for myofibroblastic tumor is surgery, and recurrence is known to be rare. The optimal treatment method is not well-known for patients ineligible for surgery. We report a 47-year-old patient with aggressive recurrent IMT of the lungs. The patient had been admitted for an evaluation of back-pain two years after a complete resection of pulmonary IMT. Radiation therapy was performed for multiple bone recurrences, and the symptoms were improved. However the patient presented again with aggravated back-pain six months later. High-dose steroid and non-steroidal anti-inflammatory drugs were administered, but the disease progressed aggressively, resulting in spinal cord compression and metastasis to intra-abdominal organs. This is a very rare case of aggressively recurrent pulmonary IMT with multi-organ metastasis.
Cerfolio RJ, Allen MS, Nascimento AG, Deschamps C, Trastek VF, Miller DL, et al. Inflammatory pseudotumors of the lung. Ann Thorac Surg 1999;67:933-6.
Hagenstad CT, Kilpatrick SE, Pettenati MJ, Savage PD. Inflammatory myofibroblastic tumor with bone marrow involvement: a case report and review of the literature. Arch Pathol Lab Med 2003;127:865-7.
Kim DY, Park HS, Kim SM, Park JH, Hong YS, Lee JL, et al. Inflammatory myofibroblastic tumor showing durable remission after anthracycline-containing cytotoxic chemotherapy: report of a case. Korean J Med 2012;82:749-53.
Sasagawa Y, Akai T, Itou S, Iizuka H. Multiple intraosseous inflammatory myofibroblastic tumors presenting with an aggressive clinical course: case report. Neurosurgery 2011;69:E1010-5.
Brunn H. Two interesting benign lung tumors of contradictory histopathology. J Thorac Surg 1939;9:119-31.
Coffin CM, Fletcher JA. Inflammatory myofibroblastic tumor. In: Fletcher CD, Unni KK, Mertens F, editors. World Health Organization classification of tumours: pathology and genetics of tumours of soft tissue and bone. Lyon: IARC Press; 2002. p. 91-3.
Coffin CM, Patel A, Perkins S, Elenitoba-Johnson KS, Perlman E, Griffin CA. ALK1 and p80 expression and chromosomal rearrangements involving 2p23 in inflammatory myofibroblastic tumor. Mod Pathol 2001;14:569-76.
Suetsugu S, Yamamoto H, Izumi M, Takayama K, Inoue H, Nakanishi Y. A case of rapidly growing inflammatory myofibroblastic tumor in the lung. Nihon Kokyuki Gakkai Zasshi 2009;47:1156-60.
Kubo N, Harada T, Anai S, Otsubo K, Yoneshima Y, Ijichi K, et al. Carboplatin plus paclitaxel in the successful treatment of advanced inflammatory myofibroblastic tumor. Intern Med 2012;51:2399-401.
Applebaum H, Kieran MW, Cripe TP, Coffin CM, Collins MH, Kaipainen A, et al. The rationale for nonsteroidal antiinflammatory drug therapy for inflammatory myofibroblastic tumors: a Children’s Oncology Group study. J Pediatr Surg 2005;40:999-1003.